CorMedix Inc.

Informe acción NasdaqGM:CRMD

Capitalización de mercado: US$581.8m

CorMedix Dirección

Dirección controles de criterios 4/4

El CEO de CorMedix es Joe Todisco , nombrado en May 2022, tiene una permanencia de 3.92 años. compensación anual total es $2.36M, compuesta por 27.1% salario y 72.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.51% de las acciones de la empresa, por valor de $2.95M. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 4.1 años, respectivamente.

Información clave

Joe Todisco

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO27.09%
Permanencia del CEO3.9yrs
Participación del CEO0.5%
Permanencia media de la dirección2.2yrs
Promedio de permanencia en la Junta Directiva4.1yrs

Actualizaciones recientes de la dirección

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade)

Apr 02

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.

CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%

Feb 06
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%

CorMedix Inc.'s (NASDAQ:CRMD) 28% Jump Shows Its Popularity With Investors

Dec 23
CorMedix Inc.'s (NASDAQ:CRMD) 28% Jump Shows Its Popularity With Investors

Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position

Aug 14
Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position

It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD)

Aug 09
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD)

Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Jun 27
Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
User avatar

DefenCath Launch Will Boost Inpatient And Dialysis Opportunities

Strong revenue growth prospects from DefenCath's successful launch and expansion into new segments like inpatient facilities and partnerships.

The Hidden Risks Behind CorMedix's First Profitable Quarter

Mar 26

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jan 17
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix: Finally In Commercialization Mode

Jan 07

CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark

Dec 13
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

CorMedix 2.0: New Leadership, New Approval, New Focus

Oct 28

CorMedix: Delayed Approval, Low Cash, Good Prospects

Oct 19

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Joe Todisco en comparación con los beneficios de CorMedix?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2025n/an/a

US$162m

Sep 30 2025n/an/a

US$162m

Jun 30 2025n/an/a

US$51m

Mar 31 2025n/an/a

US$17m

Dec 31 2024US$2mUS$639k

-US$18m

Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$2mUS$617k

-US$46m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$3mUS$378k

-US$30m

Compensación vs. Mercado: La compensación total ($USD2.36M) de Joe está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.40M).

Compensación vs. Ingresos: La compensación de Joe ha sido consistente con los resultados de la empresa en el último año.

CEO

Joe Todisco (49 yo)

3.9yrs
Permanencia
US$2,359,909
Compensación

Mr. Joseph Todisco, also known as Joe, MBA, serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022 and is its Chairman of the Board of Directors from January, 2026. He is a Director of Talph...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Joseph Todisco
CEO & Chairman of the Board of Directors3.9yrsUS$2.36m0.51%
$ 3.0m
Elizabeth Masson-Hurlburt
Executive VP2.2yrsUS$1.14m0.081%
$ 473.0k
Matthew David
EVP & Chief Business Officerless than a yearUS$1.09m0.034%
$ 199.2k
Susan Blum
EVP & Chief Financial Officerless than a yearsin datos0.011%
$ 62.1k
Kaufman Zelnick
EVP, Chief Legal and Compliance Officer & Corporate Secretary2.3yrssin datos0.14%
$ 807.7k
Beth Steinbrenner
SVP & Chief Human Resource Officerless than a yearsin datossin datos
Donna Ucci
Senior VP & Head of Global Quality3.9yrssin datossin datos
Tushar Mukherjee
Senior VP & Head of Technical Operations3.3yrssin datossin datos
Michael Seckler
EVP & Chief Commercial Officerless than a yearsin datossin datos
Peter Sullivan
Senior Vice President of Market Accessno datasin datossin datos
Jared Crandon
Executive Director of Clinical Portfolio Managementno datasin datossin datos
2.2yrs
Permanencia media
50.5yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de CRMD se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Joseph Todisco
CEO & Chairman of the Board of Directors4.1yrsUS$2.36m0.51%
$ 3.0m
Myron Kaplan
Lead Independent Director10yrsUS$210.56k0.29%
$ 1.7m
Alan Dunton
Independent Director7.1yrsUS$153.56k0.051%
$ 296.3k
Janet Dillione
Independent Director10.7yrsUS$159.56k0.049%
$ 283.2k
Steven Lefkowitz
Independent Director8.8yrsUS$174.56k0.12%
$ 717.6k
Gregory Duncan
Independent Director5.4yrsUS$153.56k0.048%
$ 282.1k
Bruce Polsky
Member of Scientific Advisor Boardno datasin datossin datos
Saravanan Balamuthusamy
Member of Scientific Advisory Board4yrssin datossin datos
Sara Bonnes
Member of Scientific Advisory Board4yrssin datossin datos
Aru Narendran
Member of Scientific Advisory Board4yrssin datossin datos
Hannah Newman
Member of Scientific Advisory Board4yrssin datossin datos
Jonathan Waitman
Member of Scientific Advisory Board4yrssin datossin datos
4.1yrs
Permanencia media
69yo
Promedio de edad

Junta con experiencia: La junta directiva de CRMD se considera experimentada (4.1 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/04/10 02:23
Precio de las acciones al final del día2026/04/10 00:00
Beneficios2025/12/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

CorMedix Inc. está cubierta por 18 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Andrew D'SilvaB. Riley Securities, Inc.
Jason ButlerCitizens JMP Securities, LLC
Jason KolbertD. Boral Capital LLC.